BENEFICIAL EFFECTS OF BEXAGLIFLOZIN, AN SGLT2 INHIBITOR, NEW MOLECULE

Dear my friends and fellow Colleagues, Here is an update on BEXAGLIFLOZIN, an SGLT2 INHIBITOR in trials, about to come soon in the USA Market. In high-risk T2D pts, Bexagliflozin was well tolerated and improved 1) HbA1c, 2) SBP, 3) Weight. Non-inferiority was demonstrated for 1) MACE+, 2) With point-estimates for MACE+ and 3) CV death or 4) HHF, HF hospitalization similar to other SGLT2 inhibitors. Reference Diabetes Jun 2020, 69 (Supplement 1) 32-OR Regards and thanks, Dr Sepuri Krishna Mohan.

2 Likes

LikeAnswersShare

Good information Sir BEXA appears to be at par with other Sglt2i Plz lets know what plus points are there

Dear sir, It's another SGLT2Inhibitor with all the benefits of SGLT2Inhibitors. Once it comes into the market,then we will be able to get more and more information about Bexagliflozin. Like Ertugliflozin disappointed in VERTIS TRIAL. Let's wait and watch sir Regards and thanks, Dr Sepuri Krishna Mohan
0

View 2 other replies

Informative sir

Thank you doctor
0

Your timely information and updates are a guiding force to us. Thanks so sharing.

Valuable opinion
0

Can it be used if the eGFR is around 40

Cut off of eGFR is 45 ml/mt sir
0

View 1 other reply

Informative and valuable post sir

Thank you doctor
0

Nice post

Thank you doctor
0